Profound changes in drug metabolizing enzyme expression occurs during development that impacts drug efficacy and the risk of adverse events in the neonate and young child. A review of our current knowledge suggests individual hepatic drug metabolizing enzymes can be categorized into one of three classes based on developmental trajectories. The time frame for the perinatal changes observed for both Class 1 and Class 3 enzymes varies considerably between different enzymes. However, for a given enzyme, significant interindividual variation is observed in the timing of the perinatal changes, creating windows of hypervariability. Genetic variation clearly impacts drug disposition in children. However, developmental factors can dominate pharmacog...
The activity of drug-metabolizing enzymes (DME) shows high inter- and intra-individual variability. ...
In addition to size-dependent allometric metabolic activity, most isoenzymes display age-dependent i...
Although some patterns are beginning to emerge, our knowl-edge of human phase I drug-metabolizing en...
Profound changes in drug metabolizing enzyme expression occurs during development that impacts drug ...
Introduction: There are profound changes that take place in drug metabolism enzymes during fetal and...
The liver represents a major eliminating and detoxifying organ, determining exposure to endogenous c...
The concept of precision or personalized medicine in pediatrics is still in its infancy, and due to ...
Pharmacokinetics (PK) of xenobiotics can differ widely between children and adults due to physiologi...
It is well recognized that expression of enzymes varies during development and growth. However, an i...
Capturing ontogeny of enzymes involved in phase I metabolism is crucial to improve prediction of dos...
Newborns are a particularly vulnerable population. The response to a drug in terms of efficacy and t...
The goal of rational drug therapy is to produce a desired pharmacological response in an acceptable ...
Item does not contain fulltextLimited understanding of drug pharmacokinetics in children is one of t...
<p><span>Genetic variation is an important determinant affecting the individual response to drugs. C...
Enzymes, receptors, and other proteins have their own distinct developmental pro-files. Consequently...
The activity of drug-metabolizing enzymes (DME) shows high inter- and intra-individual variability. ...
In addition to size-dependent allometric metabolic activity, most isoenzymes display age-dependent i...
Although some patterns are beginning to emerge, our knowl-edge of human phase I drug-metabolizing en...
Profound changes in drug metabolizing enzyme expression occurs during development that impacts drug ...
Introduction: There are profound changes that take place in drug metabolism enzymes during fetal and...
The liver represents a major eliminating and detoxifying organ, determining exposure to endogenous c...
The concept of precision or personalized medicine in pediatrics is still in its infancy, and due to ...
Pharmacokinetics (PK) of xenobiotics can differ widely between children and adults due to physiologi...
It is well recognized that expression of enzymes varies during development and growth. However, an i...
Capturing ontogeny of enzymes involved in phase I metabolism is crucial to improve prediction of dos...
Newborns are a particularly vulnerable population. The response to a drug in terms of efficacy and t...
The goal of rational drug therapy is to produce a desired pharmacological response in an acceptable ...
Item does not contain fulltextLimited understanding of drug pharmacokinetics in children is one of t...
<p><span>Genetic variation is an important determinant affecting the individual response to drugs. C...
Enzymes, receptors, and other proteins have their own distinct developmental pro-files. Consequently...
The activity of drug-metabolizing enzymes (DME) shows high inter- and intra-individual variability. ...
In addition to size-dependent allometric metabolic activity, most isoenzymes display age-dependent i...
Although some patterns are beginning to emerge, our knowl-edge of human phase I drug-metabolizing en...